|
|
News Breaks | | | | November 13, 2012 | | 07:33 EDT |  | VPHM | ViroPharma's Cinryze prophylaxis study showed safety data of escalating doses
ViroPharma announced important data from an open-label, multicenter study to assess the safety, tolerability, and treatment effect of escalating doses of C1 INH-nf in patients with HAE who were not adequately controlled with 1000 U every 3 or 4 days. The results of this study were presented at the 2012 annual meeting of the American College of Allergy, Asthma and Immunology, or ACAAI, in Anaheim, California. The data provide evidence for the safety profile of Cinryze, or C1 esterase inhibitor [human], at doses up to 2500 units in patients with hereditary angioedema, or HAE. The study was a post marketing FDA requirement to assess the safety and tolerability of escalating doses of Cinryze, with specific interest in thrombogenicity and immunogenicity. | |
|
News For VPHM From The Last 14 Days Check below for free stories on VPHM the last two weeks. |
|
|
| June 17, 2013 | | 16:20 EDT |  | VPHM | On The Fly: Closing Wrap
Stocks on Wall Street were higher following a session dominated by speculation over what is next for the Federal Reserve. The averages trimmed their gains after an article by the Financial Times suggested the Fed would signal a tapering of its pace of asset purchases at its Wednesday press conference. The upward trend resumed after the article's author said the report was based on opinion and that, "The Fed does not leak anything to any journalist to steer markets - especially during blackout." ECONOMIC EVENTS: In the U.S., the New York Fed Empire State Survey for June came in at 7.40, versus expectations for a 0 reading. The NAHB housing market confidence index for June rose to 52, versus the forecast for a more modest climb to 45 from its prior 44 reading. In Europe, Germany's Bundesbank said economic indicators for April pointed to robust growth in the second quarter and business sentiment improved in May, though warned of signs that growth in Europe's largest economy would slow over the summer. COMPANY NEWS: Netflix (NFLX) and DreamWorks (DWA) both climbed after announcing a major content deal. Under the agreement, DreamWorks will provide over 300 hours of content to Netflix, which the TV and movie service expects to start broadcasting next year. After the announcement, Netflix rose $15.24, or 7.12%, to $229.23, while DreamWorks added 93c, or 4.08%, to $23.74. MAJOR MOVERS: Among the notable gainers was Kandi Technologies (KNDI), up $1.53, or 24.4%, to $7.80 after saying it will deploy 5K-10K pure electric vehicles in China within the first year of launch. Also higher were shares of ViroPharma (VPHM), up $1.71, or 6.3%, to $28.87 after Reuters said the company has attracted takeover interest, though the company is not pursuing a sale. Among the noteworthy losers was Terex (TEX), down $2.45, or 7.72%, to $29.29 after the company lowered it fiscal year earnings view. Also lower was Medivation (MDVN), down $3.45, or 6.78%, to $47.41 after Johnson & Johnson (JNJ) acquired the company's competitor, privately held Aragon Pharmaceuticals. INDICES: The Dow was up 109.67, or 0.73%, to 15,179.85; the Nasdaq was up 28.57, or 0.83%, to 3,452.13; and the S&P 500 was up 12.31, or 0.76%, to 1,639.04. | | | 13:40 EDT |  | VPHM | ViroPharma June calls active on attracting takeover interest
ViroPharma June 30 calls are active on total call volume of 1,900 contracts (210 puts). June call option implied volatility is at 58, July and August is at 48, November is at 39; above its 26-week average of 37 according to Track Data, suggesting larger price movement on the company not pursuing a sale but attracting takeover interest, Reuters says. | | | 11:37 EDT |  | VPHM | ViroPharma not pursuing sale but attracting takeover interest, Reuters says
 Subscribe for More Information | | | 11:34 EDT | | VPHM | ViroPharma up 9% after Reuters report of takeover interest
Subscribe for More Information | | | 11:33 EDT | | VPHM | ViroPharma has attracted preliminary takeover interest, Reuters reports
Subscribe for More Information | | | June 11, 2013 | | 06:20 EDT | | VPHM | ViroPharma receives Orphan drug designation for Maribavir in Europe
Subscribe for More Information | |
|
|
|
|
|
|
